GHENT, Belgium, May 28, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announces it will present at the Annual Jefferies 2015 Global Healthcare Conference in New York City on Thursday, 4 June 2015 at 09:30 a.m. EST (03:30 p.m. CET).
The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO of Ablynx. The presentation will provide an update on the Company's proprietary key clinical assets, its partnered programmes and the outlook for the near term future.
The presentation will be webcast live and can be accessed on the day via this link. A replay of the webcast will be available on the Company's website, under the news & events section, for 90 days following the presentation. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co, Inc., Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact Ablynx:
Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Jonathan Birt, Chris Welsh, Lindsey Neville
t: +44 203 709 5700
pdf format of the press release http://hugin.info/137912/R/1924298/690218.pdf